《Science,7月10日,Estimating the burden of SARS-CoV-2 in France》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-07-28
  • Estimating the burden of SARS-CoV-2 in France

    Henrik Salje1,2,3,*, Cécile Tran Kiem1,4,*, Noémie Lefrancq1, Noémie Courtejoie5, Paolo Bosetti1, Juliette Pair

    Science 10 Jul 2020:

    Vol. 369, Issue 6500, pp. 208-211

    DOI: 10.1126/science.abc3517

    Abstract

    France has been heavily affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and went into lockdown on 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find that 2.9% of infected individuals are hospitalized and 0.5% of those infected die (95% credible interval: 0.3 to 0.9%), ranging from 0.001% in those under 20 years of age to 8.3% in those 80 years of age or older. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project that 3.5 million people (range: 2.1 million to 6.0 million), or 5.3% of the population (range: 3.3 to 9.3%), will have been infected. Population immunity appears to be insufficient to avoid a second wave if all control measures are released at the end of the lockdown.

  • 原文来源:https://science.sciencemag.org/content/369/6500/208
相关报告
  • 《7月10日_科学家估算法国SARS-CoV-2的负担》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-07-28
    • 7月10日,Science期刊发表题为“Estimating the burden of SARS-CoV-2 in France”的文章。文章指出,法国受到SARS-CoV-2大流行的严重影响,于2020年3月17日进入封锁状态。研究人员利用适用于医院和死亡数据的模型,估计了封锁的影响和当前人群免疫力。文章称,研究人员发现,2.9%的感染者住院,0.5%的感染者死亡(95%置信区间:0.3%~0.9%),从20岁以下人群的0.001%到80岁及以上人群的8.3%不等。在所有年龄段中,男性比女性更容易住院、进入重症监护室和死亡。封锁将传染数从2.90降低到0.67(减少77%)。研究人员预测,到2020年5月11日,法国计划放松干预时,有350万人(范围:210万至600万),或5.3%的人口(范围:3.3%至9.3%)被感染。如果在封锁结束时解除所有控制措施,人口的免疫力似乎不足以避免第二波冲击。 原文链接:https://science.sciencemag.org/content/369/6500/208
  • 《Science,7月23日,Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-07-28
    • Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody Zhe Lv1,8,*, Yong-Qiang Deng2,*, Qing Ye2,*, Lei Cao1,*, Chun-Yun Sun3,*, Changfa Fan4,*, Weijin Hua Science 23 Jul 2020: eabc5881 DOI: 10.1126/science.abc5881 Abstract The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we reported a humanized monoclonal antibody, H014, efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nM level by engaging the S receptor binding domain (RBD). Importantly, H014 administration reduced SARS-CoV-2 titers in the infected lungs and prevented pulmonary pathology in hACE2 mouse model. Cryo-EM characterization of the SARS-CoV-2 S trimer in complex with the H014 Fab fragment unveiled a novel conformational epitope, which is only accessible when the RBD is in open conformation. Biochemical, cellular, virological and structural studies demonstrated that H014 prevents attachment of SARS-CoV-2 to its host cell receptors. Epitope analysis of available neutralizing antibodies against SARS-CoV and SARS-CoV-2 uncover broad cross-protective epitopes. Our results highlight a key role for antibody-based therapeutic interventions in the treatment of COVID-19.